JP2004502409A5 - - Google Patents

Download PDF

Info

Publication number
JP2004502409A5
JP2004502409A5 JP2001580185A JP2001580185A JP2004502409A5 JP 2004502409 A5 JP2004502409 A5 JP 2004502409A5 JP 2001580185 A JP2001580185 A JP 2001580185A JP 2001580185 A JP2001580185 A JP 2001580185A JP 2004502409 A5 JP2004502409 A5 JP 2004502409A5
Authority
JP
Japan
Prior art keywords
variable region
ferm
amino acid
seq
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001580185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004502409A (ja
JP4156238B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/014151 external-priority patent/WO2001083560A1/en
Publication of JP2004502409A publication Critical patent/JP2004502409A/ja
Publication of JP2004502409A5 publication Critical patent/JP2004502409A5/ja
Application granted granted Critical
Publication of JP4156238B2 publication Critical patent/JP4156238B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001580185A 2000-05-02 2001-05-02 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターについて選択的な抗体、およびそれらの使用 Expired - Lifetime JP4156238B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20134400P 2000-05-02 2000-05-02
PCT/US2001/014151 WO2001083560A1 (en) 2000-05-02 2001-05-02 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005113535A Division JP3892466B2 (ja) 2000-05-02 2005-04-11 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途
JP2006315093A Division JP2007091749A (ja) 2000-05-02 2006-11-22 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途

Publications (3)

Publication Number Publication Date
JP2004502409A JP2004502409A (ja) 2004-01-29
JP2004502409A5 true JP2004502409A5 (enExample) 2007-02-01
JP4156238B2 JP4156238B2 (ja) 2008-09-24

Family

ID=22745456

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001580185A Expired - Lifetime JP4156238B2 (ja) 2000-05-02 2001-05-02 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターについて選択的な抗体、およびそれらの使用
JP2005113535A Expired - Lifetime JP3892466B2 (ja) 2000-05-02 2005-04-11 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途
JP2006315093A Pending JP2007091749A (ja) 2000-05-02 2006-11-22 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途
JP2008194948A Expired - Lifetime JP4575975B2 (ja) 2000-05-02 2008-07-29 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2005113535A Expired - Lifetime JP3892466B2 (ja) 2000-05-02 2005-04-11 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途
JP2006315093A Pending JP2007091749A (ja) 2000-05-02 2006-11-22 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途
JP2008194948A Expired - Lifetime JP4575975B2 (ja) 2000-05-02 2008-07-29 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途

Country Status (27)

Country Link
US (6) US7244429B2 (enExample)
EP (4) EP1287035B1 (enExample)
JP (4) JP4156238B2 (enExample)
KR (2) KR20060092292A (enExample)
CN (2) CN100497388C (enExample)
AT (1) ATE426615T1 (enExample)
AU (2) AU2001259366B2 (enExample)
BG (3) BG65929B1 (enExample)
BR (1) BR0110547A (enExample)
CA (1) CA2407965C (enExample)
CY (1) CY1109179T1 (enExample)
CZ (2) CZ304614B6 (enExample)
DE (1) DE60138097D1 (enExample)
DK (1) DK1287035T3 (enExample)
EE (1) EE05548B1 (enExample)
ES (1) ES2323448T3 (enExample)
HU (2) HU229417B1 (enExample)
IL (1) IL152605A0 (enExample)
MX (1) MXPA02010823A (enExample)
NO (2) NO329843B1 (enExample)
NZ (1) NZ522881A (enExample)
PL (1) PL211733B1 (enExample)
PT (1) PT1287035E (enExample)
RU (1) RU2298013C2 (enExample)
TW (1) TWI318983B (enExample)
WO (1) WO2001083560A1 (enExample)
ZA (1) ZA200209230B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
NZ337795A (en) 1997-03-17 2001-06-29 Human Genome Sciences Inc Death domain containing receptor 5 and it's use in the treatment of DR5 related disease
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
WO2000066156A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
JP3665316B2 (ja) * 2001-05-18 2005-06-29 麒麟麦酒株式会社 抗ｔｒａｉｌ−ｒ抗体
DK1572874T3 (da) 2001-05-25 2013-12-16 Human Genome Sciences Inc Antistoffer, der immunospecifikt binder til TRAIL receptorer
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
CA2463816C (en) 2001-10-19 2014-07-08 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
NZ533164A (en) * 2001-11-01 2008-09-26 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
DE10210427A1 (de) * 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
CA2491669A1 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
DE60334247D1 (de) * 2002-11-27 2010-10-28 Irm Llc Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
EP1756162A1 (en) * 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
CN100427505C (zh) * 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
CN101065401B (zh) * 2004-12-13 2012-10-24 赛弗隆澳大利亚(Vic)私人有限公司 骨保护素变异蛋白
EP1846034A4 (en) 2005-02-02 2010-11-10 Uab Research Foundation AGENTS AND METHODS OF REDUCING THE RESISTANCE TO APOPTOSIS INDUCING DEATH RECEPTOR AGONISTS
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP5004154B2 (ja) * 2005-04-06 2012-08-22 一般財団法人化学及血清療法研究所 組換え抗ボツリヌス神経毒素抗体
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
CN101300273B (zh) * 2005-08-31 2013-05-22 安姆根有限公司 Trail受体2多肽和抗体
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US8232377B2 (en) 2006-05-16 2012-07-31 National Institute Of Advanced Industrial Science And Technology Method for high-level secretory production of protein
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
KR100847010B1 (ko) * 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
KR100804126B1 (ko) 2007-02-09 2008-02-19 아주대학교산학협력단 종양 괴사 인자―관련 세포사멸―유도 리간드의 수용체에특이적으로 결합하는 1가의 인간 단일클론 항체 및 그의항원결합 단편
WO2008154439A1 (en) * 2007-06-08 2008-12-18 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
EP2177230A4 (en) * 2007-08-09 2011-04-27 Daiichi Sankyo Co Ltd IMMUNOLIPOSOM AS INDUCTOR OF APOPTOSIS INTO DEATH DOMAIN-CONTAINING RECEPTOR EXPRESSING CELL
EP2210940B2 (en) 2007-10-31 2018-07-18 Daiichi Sankyo Company, Limited Method for high-level secretion and production of protein
WO2010047509A2 (ko) * 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
CA2775350A1 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
KR101278690B1 (ko) * 2009-10-19 2013-06-24 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
WO2011084623A1 (en) 2009-12-16 2011-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
CN103282495B (zh) 2010-10-29 2017-06-09 第一三共株式会社 新的抗dr5抗体
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
MX2013012716A (es) * 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
WO2014012165A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
SG11201500489YA (en) * 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
CN103074425B (zh) * 2012-12-29 2014-01-01 深圳市第三人民医院 Cd263基因的用途
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN104710533A (zh) * 2013-12-12 2015-06-17 中国科学院深圳先进技术研究院 sDR5-Fc融合蛋白及其用途
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
CN105061604B (zh) * 2015-08-19 2018-03-16 河南大学 sDR5‑Fc融合蛋白突变体及其应用
WO2017075484A2 (en) 2015-10-30 2017-05-04 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4 and death receptor 5
MX2018006333A (es) 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
CN106924735A (zh) * 2015-12-29 2017-07-07 上海交通大学医学院附属瑞金医院 多巴胺1类受体激动剂在制备肿瘤治疗药物中的用途
US10849912B2 (en) 2016-02-09 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
KR101926834B1 (ko) 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
CN111328335A (zh) 2017-06-07 2020-06-23 根马布私人有限公司 基于突变igg六聚体的治疗性抗体
KR101951025B1 (ko) 2017-08-17 2019-02-21 서울대학교산학협력단 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
TWI826393B (zh) * 2017-09-22 2023-12-21 美商免疫遺傳股份有限公司 使用陽離子交換層析法分離三輕鏈抗體
WO2019100193A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗体及其制备方法和应用
WO2019100194A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗体及其制备方法和应用
CN108251443A (zh) * 2018-01-23 2018-07-06 深圳市人民医院 一种tnfrsf10c重组质粒、制备方法及其应用
WO2019173499A1 (en) 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
CN117003874A (zh) 2018-03-20 2023-11-07 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
EP4277706A1 (en) 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
NZ337795A (en) 1997-03-17 2001-06-29 Human Genome Sciences Inc Death domain containing receptor 5 and it's use in the treatment of DR5 related disease
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
AU734758B2 (en) 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
CA2287085A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
JP2001510042A (ja) * 1997-07-15 2001-07-31 イミュネックス・コーポレーション Ｔｒａｉｌ受容体
WO1999007861A1 (en) 1997-08-06 1999-02-18 Laboratório Medinfar-Produtos Farmacêuticos, Lda. DNA INTEGRATION INTO 'MYCOBACTERIUM spp.' GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM
AU8861898A (en) * 1997-08-13 1999-03-08 Ufe Solar Gmbh Sorption trap arrangement and method for storing heat
WO1999009165A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP4357738B2 (ja) 1997-09-12 2009-11-04 アポテック エール エ デ− エス．アー． システインリッチなレセプターであるｔｒａｉｎ
US7105640B2 (en) * 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
US20040120947A1 (en) 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
IL137176A0 (en) 1998-01-26 2001-07-24 Genentech Inc Antibodies to 4dr and uses thereof
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US6534061B1 (en) 1999-04-12 2003-03-18 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
WO2000066156A1 (en) 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
AU4984300A (en) 1999-05-06 2000-11-21 Vishva M Dixit Death domain containing receptor 4
DK1181319T3 (da) 1999-05-28 2009-08-17 Genentech Inc Kimære DR4-antistoffer og anvendelser deraf
PT1192185E (pt) 1999-06-09 2006-11-30 Genentech Inc Sinergismo de agonista do receptor de apo-2l e cpt-11
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
EP1226161A2 (en) 1999-09-15 2002-07-31 Genentech, Inc. Apo-2 receptor antibodies
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
CA2426710A1 (en) 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6965023B2 (en) * 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
EP1409544B1 (en) 2001-07-03 2009-06-17 Genentech, Inc. Human dr4 antibodies and uses thereof
NZ533164A (en) 2001-11-01 2008-09-26 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.

Similar Documents

Publication Publication Date Title
JP2004502409A5 (enExample)
RU2009128064A (ru) Антитела к cd44
JP2008529529A5 (enExample)
JP2010533498A5 (enExample)
JP2011510654A5 (enExample)
JP2023093753A5 (enExample)
JP2020525032A5 (enExample)
CN115461368A (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
JP2010532764A5 (enExample)
JP2008511291A5 (enExample)
JP2008516970A5 (enExample)
JP2003503017A5 (enExample)
JP2002503495A5 (enExample)
JP2012501669A5 (enExample)
JP2020519308A5 (enExample)
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение
JP2007510664A5 (enExample)
US11597763B2 (en) Anti-Kv1.3 antibodies, and methods of production and use thereof
JP2024095774A5 (enExample)
JP2020515277A5 (enExample)
JP2003501030A5 (enExample)
CA2402593A1 (en) Monoclonal antibodies to the human ldl receptor, their production and use
JP2003521219A5 (enExample)
IL277899B2 (en) Methods and preparations for treating yellow fever
CN110396131B (zh) 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用